BIOCARDIA INC (BCDA)

US09060U6064 - Common Stock

2.16  -0.09 (-4%)

Fundamental Rating

2

Taking everything into account, BCDA scores 2 out of 10 in our fundamental rating. BCDA was compared to 572 industry peers in the Biotechnology industry. BCDA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BCDA is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BCDA has reported negative net income.
In the past year BCDA has reported a negative cash flow from operations.
BCDA had negative earnings in each of the past 5 years.
In the past 5 years BCDA always reported negative operating cash flow.

1.2 Ratios

BCDA has a Return On Assets of -123.22%. This is amonst the worse of the industry: BCDA underperforms 80.53% of its industry peers.
BCDA's Return On Equity of -280.49% is on the low side compared to the rest of the industry. BCDA is outperformed by 73.81% of its industry peers.
Industry RankSector Rank
ROA -123.22%
ROE -280.49%
ROIC N/A
ROA(3y)-196.44%
ROA(5y)-168.98%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BCDA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

BCDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BCDA has less shares outstanding
BCDA has less shares outstanding than it did 5 years ago.
BCDA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -37.22, we must say that BCDA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -37.22, BCDA is doing worse than 92.74% of the companies in the same industry.
BCDA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -37.22
ROIC/WACCN/A
WACC10.88%

2.3 Liquidity

A Current Ratio of 1.78 indicates that BCDA should not have too much problems paying its short term obligations.
The Current ratio of BCDA (1.78) is worse than 79.29% of its industry peers.
A Quick Ratio of 1.78 indicates that BCDA should not have too much problems paying its short term obligations.
BCDA has a worse Quick ratio (1.78) than 77.88% of its industry peers.
Industry RankSector Rank
Current Ratio 1.78
Quick Ratio 1.78

More info and screens

4

3. Growth

3.1 Past

BCDA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.91%, which is quite good.
Looking at the last year, BCDA shows a very negative growth in Revenue. The Revenue has decreased by -87.54% in the last year.
Measured over the past years, BCDA shows a decrease in Revenue. The Revenue has been decreasing by -5.41% on average per year.
EPS 1Y (TTM)17.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.11%
Revenue 1Y (TTM)-87.54%
Revenue growth 3Y47.05%
Revenue growth 5Y-5.41%
Sales Q2Q%-100%

3.2 Future

BCDA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.37% yearly.
The Revenue is expected to grow by 70.56% on average over the next years. This is a very strong growth
EPS Next Y56.48%
EPS Next 2Y35.98%
EPS Next 3Y22.44%
EPS Next 5Y13.37%
Revenue Next Year-82.82%
Revenue Next 2Y-58.55%
Revenue Next 3Y-44.41%
Revenue Next 5Y70.56%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BCDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BCDA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

BCDA's earnings are expected to grow with 22.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.98%
EPS Next 3Y22.44%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BCDA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOCARDIA INC

NASDAQ:BCDA (1/14/2025, 8:25:24 PM)

2.16

-0.09 (-4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Inst Owners2.47%
Inst Owner Change0%
Ins Owners13.37%
Ins Owner Change1.9%
Market Cap9.89M
Analysts82.86
Price Target25.5 (1080.56%)
Short Float %1.29%
Short Ratio1.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-625%
EPS NY rev (1m)0%
EPS NY rev (3m)30.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-80%
Revenue NY rev (3m)-80%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 139.34
P/FCF N/A
P/OCF N/A
P/B 3.59
P/tB 3.59
EV/EBITDA N/A
EPS(TTM)-8.25
EYN/A
EPS(NY)-1.24
Fwd EYN/A
FCF(TTM)-1.6
FCFYN/A
OCF(TTM)-1.6
OCFYN/A
SpS0.02
BVpS0.6
TBVpS0.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -123.22%
ROE -280.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-196.44%
ROA(5y)-168.98%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.21%
Cap/Sales 9.86%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.78
Quick Ratio 1.78
Altman-Z -37.22
F-Score4
WACC10.88%
ROIC/WACCN/A
Cap/Depr(3y)100.6%
Cap/Depr(5y)96.2%
Cap/Sales(3y)6.49%
Cap/Sales(5y)12.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.11%
EPS Next Y56.48%
EPS Next 2Y35.98%
EPS Next 3Y22.44%
EPS Next 5Y13.37%
Revenue 1Y (TTM)-87.54%
Revenue growth 3Y47.05%
Revenue growth 5Y-5.41%
Sales Q2Q%-100%
Revenue Next Year-82.82%
Revenue Next 2Y-58.55%
Revenue Next 3Y-44.41%
Revenue Next 5Y70.56%
EBIT growth 1Y38.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year26.02%
EBIT Next 3Y0.03%
EBIT Next 5Y-1.61%
FCF growth 1Y31.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.67%
OCF growth 3YN/A
OCF growth 5YN/A